PHARMACOTHERAPY IN PATIENTS WITH ERECTILE DYSFUNCTION AND BENIGN PROSTATIC HYPERPLASIA IN THE ABSENCE OF RISK OF DISEASE PROGRESSION
Purpose. Evaluation of the effectiveness and safety of various pharmacotherapy options in patients with erectile dysfunction (ED) in combination with benign prostatic hyperplasia (BPH).Materials and methods. In 127 men with BPH and ED, pharmacotherapy was performed for 3–12 months. Inclusion criteri...
Saved in:
Main Authors: | A. A. Kamalov, A. M. Tahirzade |
---|---|
Format: | Article |
Language: | Russian |
Published: |
QUASAR, LLC
2018-03-01
|
Series: | Исследования и практика в медицине |
Subjects: | |
Online Access: | https://www.rpmj.ru/rpmj/article/view/239 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Rauwolfia vomitoria- a promising medical plant for benign prostatic hyperplasia management; yet with challenges
by: George Awuku Asare, et al.
Published: (2025-02-01) -
Urology pathways for the primary care physician
by: J John
Published: (2024-04-01) -
Thulium laser enucleation of the prostate plus thulium fiber laser therapy for benign prostatic hyperplasia combined with bladder stones
by: Chen Wang, et al.
Published: (2024-08-01) -
Mechanisms of L-citrulline on phosphodiesterase 5 in erectile dysfunction intervention
by: Abdulhakeem Olarewaju Sulyman, et al.
Published: (2025-03-01) -
Burden of benign prostatic hyperplasia in the Middle East and North Africa Region, 1990–2021
by: Saeid Safiri, et al.
Published: (2025-02-01)